Improving Mycobacterium bovis Bacillus Calmette-Guèrin as a Vaccine Delivery Vector for Viral Antigens by Incorporation of Glycolipid Activators of NKT Cells

Article English OPEN
Venkataswamy, Manjunatha M.; Ng, Tony W.; Kharkwal, Shalu S.; Carreño, Leandro J.; Johnson, Alison J.; Kunnath-Velayudhan, Shajo; Liu, Zheng; Bittman, Robert; Jervis, Peter J.; Cox, Liam R.; Besra, Gurdyal S.; Wen, Xiangshu; Yuan, Weiming; Tsuji, Moriya; Li, Xiangming; Ho, David D.; Chan, John; Lee, Sunhee; Frothingham, Richard; Haynes, Barton F.; Panas, Michael W.; Gillard, Geoffrey O.; Sixsmith, Jaimie D.; Korioth-Schmitz, Birgit; Schmitz, Joern E.; Larsen, Michelle H.; Jacobs, William R.; Porcelli, Steven A.;
  • Publisher: Public Library of Science
  • Journal: PLoS ONE,volume 9,issue 9 (issn: 1932-6203, eissn: 1932-6203)
  • Related identifiers: pmc: PMC4177913, doi: 10.1371/journal.pone.0108383., doi: 10.1371/journal.pone.0108383
  • Subject: Immunomodulation | Biology and Life Sciences | Research Article | Vaccine Development | Vaccines | Medicine | Vaccination and Immunization | Recombinant Vaccines | Immunologic Adjuvants | Q | R | Clinical Immunology | Science | Immunology | Infectious Disease Immunology

Recombinant Mycobacterium bovis bacillus Calmette-Guèrin (rBCG) has been explored as a vector for vaccines against HIV because of its ability to induce long lasting humoral and cell mediated immune responses. To maximize the potential for rBCG vaccines to induce effecti... View more